Ken Griffin Celldex Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 28,600 shares of CLDX stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,600
Previous 69,500
58.85%
Holding current value
$1.11 Million
Previous $2.76 Million
56.46%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CLDX
# of Institutions
208Shares Held
61.1MCall Options Held
291KPut Options Held
246K-
Wellington Management Group LLP Boston, MA7.65MShares$297 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.51MShares$175 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$142 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.12MShares$121 Million2.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$120 Million0.02% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.82B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...